AssetMark’s Axsome Therapeutics AXSM Stock Holding History
Bought
Maintained
Sold
Other funds holding AXSM
AssetMark's AXSM Position: Q3 2026 in Review
AssetMark increased its Axsome Therapeutics (AXSM) stake by 292% in Q3 2026, buying an estimated $801K and bringing the position to 4,939 shares worth $911K. The position accounts for ﹤0.01% of the portfolio, ranked #1109.
AssetMark first reported a position in AXSM in Q4 2024 and has held it in 8 quarters since. 348 funds tracked by Wall St. Rank hold AXSM as of Q3 2026.
- AssetMark held 4,939 shares of Axsome Therapeutics worth $911K as of Q3 2026.
- AssetMark bought 3,680 Axsome Therapeutics shares in Q3 2026, an estimated $801K.
- Axsome Therapeutics made up ﹤0.01% of AssetMark's portfolio in Q3 2026, its #1109 holding.
- AssetMark first reported a position in Axsome Therapeutics in Q4 2024 and has held it in 8 quarters since.
- 348 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q3 2026.
Based on AssetMark's 13F filing for Q3 2026, filed 21 Oct 2026.